China Regenerative Medicine International Management
Management criteria checks 4/4
China Regenerative Medicine International's CEO is Chuang Wang, appointed in Jul 2020, has a tenure of 3.25 years. directly owns 19.29% of the company’s shares, worth HK$36.33M. The average tenure of the management team and the board of directors is 4.1 years and 3.8 years respectively.
Key information
Chuang Wang
Chief executive officer
HK$1.2m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.3yrs |
| CEO ownership | 19.3% |
| Management average tenure | 4.1yrs |
| Board average tenure | 3.8yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | HK$15m |
| Mar 31 2023 | n/a | n/a | HK$5m |
| Dec 31 2022 | HK$1m | n/a | HK$5m |
| Sep 30 2022 | n/a | n/a | HK$31m |
| Jun 30 2022 | n/a | n/a | HK$26m |
| Mar 31 2022 | n/a | n/a | HK$49m |
| Dec 31 2021 | HK$1m | n/a | HK$52m |
| Sep 30 2021 | n/a | n/a | -HK$95m |
| Jun 30 2021 | n/a | n/a | -HK$82m |
| Mar 31 2021 | n/a | n/a | -HK$105m |
| Dec 31 2020 | HK$1m | n/a | -HK$120m |
| Sep 30 2020 | n/a | n/a | -HK$201m |
| Jun 30 2020 | n/a | n/a | -HK$237m |
| Mar 31 2020 | n/a | n/a | -HK$239m |
| Dec 31 2019 | HK$245k | HK$245k | -HK$264m |
Compensation vs Market: Chuang's total compensation ($USD153.40K) is below average for companies of similar size in the Hong Kong market ($USD232.81K).
Compensation vs Earnings: Chuang's compensation has been consistent with company performance over the past year.
CEO
Chuang Wang (44 yo)
3.3yrs
Tenure
HK$1,200,000
Compensation
Mr. Chuang Wang has been Executive Chairman at China Regenerative Medicine International Limited since October 18, 2019 and serves as its Chief Executive Officer since July 9, 2020 and also serves as its C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Executive Chairman & Compliance Officer | 3.3yrs | HK$1.20m | 19.29% HK$ 36.3m | |
| Chief Financial Officer | 1.1yrs | no data | no data | |
| Chief Operating Officer | 5yrs | no data | no data | |
| Chief Technology Officer | 5.1yrs | no data | no data | |
| Legal Counsel | no data | no data | no data | |
| Chairman of Stem Cell Division & Director of University of Oxford Tissue Engineering Centre | 5.1yrs | HK$500.00k | no data | |
| Company Secretary | 1.1yrs | no data | no data |
4.1yrs
Average Tenure
44yo
Average Age
Experienced Management: 8592's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Executive Chairman & Compliance Officer | 4yrs | HK$1.20m | 19.29% HK$ 36.3m | |
| Independent Non-Executive Director | 1.8yrs | HK$120.00k | no data | |
| Non-Executive Director | 3.8yrs | HK$314.00k | no data | |
| Independent Non-Executive Director | 3.8yrs | HK$120.00k | no data | |
| Independent Non-Executive Director | 1.8yrs | HK$120.00k | no data |
3.8yrs
Average Tenure
48yo
Average Age
Experienced Board: 8592's board of directors are considered experienced (3.8 years average tenure).